Cisen Pharmaceutical, the sales volume of the winning varieties in the group purchase has increased significantly. It is expected that the sales of the large infusion sector will stabilize in the second half of the year. | Live coverage of the earnings co

① At the earnings conference, the director of Cisen Pharmaceutical, Xunxin Xubing, explained the situation of the company's gross margin and revenue decline in the first half of the year; ② Xunxin Xubing stated that the sales volume of four varieties that the company won in the eighth batch of centralized procurement increased significantly compared to the same period last year; ③ The company's chairman, Du Zhenxin, introduced the situation of the company's generic drug and innovative drug research and development.

cls.cn17:55

Zhejiang Hisun Pharmaceutical: Give up the pharmaceutical distribution raw material business, leading to a decline in H1 revenue. Sales of Olsalazine increased significantly compared to the same period last year.

①At the earnings conference, the CFO of Zhejiang Hisun Pharmaceutical explained that the decline in H1 revenue was due to the company's abandonment of low-margin pharmaceutical distribution raw material business and other factors. ②President Xiao Weihong addressed questions about the growth in endocrine drug revenue and the future business model of the animal health sector.

cls.cnSep 4 21:29

chongqing zhifei biological products' 23-valent pneumonia vaccine joins the "price reduction group" just one year after its launch.

①Chongqing Zhifei Biological Products' 23-valent pneumococcal polysaccharide vaccine has been reduced by nearly 30% in the listing price in provinces such as Jiangsu and jilin; ②Currently, the pneumococcal vaccine market in China is showing a competitive situation of fierce competition between overseas MNCs and domestic enterprises, while more and more companies are entering this field; ③Industry experts believe that in order to gain market share, companies can only choose to actively reduce prices.

cls.cnSep 4 19:55

Head accounting firms have also been heavily penalized, with penalties directly related to ten violations. Currently, there are 53 IPO projects under review.

luoxin pharmaceuticals group stock's financial report audit has ten major professional issues, Tianjian Accounting Firm has been warned; Tianjian Accounting Firm is currently conducting audits for a total of 86 projects, including 53 IPO projects under review; 34 accounting firms have been fined this year, and the key is to strengthen the responsibility of the 'gatekeepers'.

cls.cnAug 30 20:24

The batch issuance of the quadrivalent HPV vaccine has dramatically decreased, and chongqing zhifei biological products' revenue and net profit have both declined. Interpretation of the financial report.

① Chongqing Zhifei Biological Products reported a decrease in revenue and net income for the first half of the year due to a decline in sales of its main product. ② The batch issuance of Merck's quadrivalent HPV vaccine, which the company represents, decreased by over 90% year-on-year. ③ As the development of domestically-produced nine-valent HPV vaccine accelerates, the company's pressure will further increase.

cls.cnAug 29 23:32

The recovery of the live pig market, ST Tianbang H1 turns loss into profit, and the pre-reorganization progresses as the company's debt decreases | interpretations

①ST Tianbang achieved a net income of 0.174 billion yuan after deducting non-recurring items in Q2, compared to a net loss of 0.455 billion yuan after deducting non-recurring items in Q1, indicating a clear improvement in the main business performance; ② The company's food business grew significantly during the reporting period, but it is still in a loss-making state; ③ The company made certain progress in reducing its liabilities, with total liabilities decreasing by 3.577 billion yuan from the beginning of the year, and the liability ratio decreased by 8.33 percentage points.

cls.cnAug 29 23:04